Harvard Apparatus Regenerative Technology Schedules Investor Teleconference for December 23, 2014, at 11:00 A.M. ET
December 22 2014 - 2:19PM
Business Wire
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART),
a clinical stage biotechnology company developing regenerated
organs for transplant, initially focused on the trachea, will hold
a conference call to discuss recent events at 11:00 AM (Eastern
Time) on December 23, 2014. On that call, management may take
questions from the audience on any of a number of topics related to
the business, including operations, plans and outlook.
Investors can access the live conference call by dialing the
following phone numbers: toll-free 888-466-4462, or
toll/international: 719-325-2308, and referencing the pass code
“3088315”.
If you are unable to listen to the live conference call, a
replay will be available from approximately 2:00 PM (Eastern Time)
on December 23, 2014 through 2:00 PM (Eastern Time) on December 30,
2014 and will be accessible by dialing toll-free 888-203-1112, or
toll/international 719-457-0820, and referencing the pass code
“3088315”. The replay will also be made available on the company’s
web site, www.hartregen.com.
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology makes regenerated
organs for transplant. Our first product, the HART-Trachea, is
intended to replace or repair a trachea that has been severely
damaged by either trachea cancer or physical trauma. Our
HART-Trachea technology has been used in six human trachea
transplants to date approved under compassionate use exemptions,
but none of our products are yet approved by a government
regulatory authority for marketing. On November 1, 2013, HART was
spun-off from Harvard Bioscience. The trademark “Harvard Apparatus”
is used under a sublicense agreement with Harvard Bioscience, who
has licensed the right to use such trademark from Harvard
University.
Harvard Apparatus Regenerative Technology, Inc.:David Green,
774-233-7320President and CEOdgreen@HARTregen.comorTom McNaughton,
774-233-7321CFOtmcnaughton@HARTregen.com
Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From Apr 2023 to Apr 2024